Evaluation of antiangiogenic treatment effects on tumors' microcirculation by Bayesian physiological pharmacokinetic modeling and magnetic resonance imaging

Magnetic Resonance Imaging

Volumn 24, Issue 8, 2006, Pages 1059-1067

  Brochot, Céline ^a   Bessoud, Bertrand ^b   Balvay, Daniel ^b   Cuénod, Charles André ^b,c   Siauve, Nathalie ^b,c   Bois, Frédéric Y ^a  

^a INSTITUT NATIONAL DE L ENVIRONNEMENT INDUSTRIEL ET DES RISQUES INERIS   (France)

^b Institut Necker   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Bayesian analysis; Dynamic MRI; PBPK model; Tumor microcirculation; Vistarem

Indexed keywords

ANGIOGENESIS INHIBITOR; GADOMELITOL; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; PLACEBO; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTERIAL BLOOD; ARTICLE; BAYES THEOREM; CANCER GRAFT; CANCER TISSUE; CAPILLARY; CONTROLLED STUDY; DATA ANALYSIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG SCREENING; IMAGE ENHANCEMENT; INTERSTITIUM; MALE; MATHEMATICAL MODEL; MICROCIRCULATION; MONTE CARLO METHOD; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PLASMA; PRIORITY JOURNAL; PROBABILITY; STATISTICAL ANALYSIS; TUMOR BLOOD FLOW;

ANIMALS; BAYES THEOREM; CONTRAST MEDIA; HETEROCYCLIC COMPOUNDS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, NUDE; MICROCIRCULATION; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOMETALLIC COMPOUNDS; QUINAZOLINES; TRIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 33748750071     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mri.2006.04.002     Document Type: Article

References (30)

1. Daldrup H.E., Shames D.M., Husseini W., Wendland M.F., Okuhata Y., and Brasch R.C. Quantification of the extraction fraction for gadopentetate across breast cancer capillaries. Magn Reson Med 40 4 (1998) 537-543
2. Taylor J.S., Tofts P.S., Port R., et al. MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging 10 6 (1999) 903-907
3. Tofts P.S., Berkowitz B., and Schnall M.D. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 33 4 (1995) 564-568
4. Gillies R.J., Bhujwalla Z.M., Evelhoch J., et al. Applications of magnetic resonance in model systems: tumor biology and physiology. Neoplasia 2 1-2 (2000) 139-151
5. Pradel C., Siauve N., Bruneteau G., et al. Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media. Magn Reson Imaging 21 8 (2003) 845-851
6. Tofts P.S. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 7 1 (1997) 91-101
7. Brix G., Semmler W., Port R., Schad L.R., Layer G., and Lorenz W.J. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J Comput Assist Tomogr 15 4 (1991) 621-628
8. Tofts P.S., and Kermode A.G. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging: 1. Fundamental concepts. Magn Reson Med 17 2 (1991) 357-367
9. Port R.E., Knopp M.V., Hoffmann U., Milker-Zabel S., and Brix G. Multicompartment analysis of gadolinium chelate kinetics: blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging. J Magn Reson Imaging 10 3 (1999) 233-241
10. Port R.E., Knopp M.V., and Brix G. Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. Magn Reson Med 45 6 (2001) 1030-1038
11. Port M., Corot C., Rousseaux O., et al. P792: a rapid clearance blood pool agent for magnetic resonance imaging: preliminary results. Magn Reson Mater Phys 12 2-3 (2001) 121-127
12. Port M., Corot C., Raynal I., et al. Physicochemical and biological evaluation of P792, a rapid-clearance blood-pool agent for magnetic resonance imaging. Invest Radiol 36 8 (2001) 445-454
13. Ludden T.M., Gillespie W.R., and Bachman W.J. Commentary on "Physiologically based pharmacokinetic modeling as a tool for drug development". J Pharmacokinet Biopharm 23 (1995) 231-235
14. Gelman A., Bois F.Y., and Jiang J. Physiological pharmacokinetic analysis using population modeling and informative prior distributions. J Am Stat Assoc 91 436 (1996) 1400-1412
15. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy. Cancer Res 60 4 (2000) 970-975
16. Davis B., and Morris T. Physiological parameters in laboratory animals and human. Pharm Res 10 7 (1993) 1093-1095
17. Bernardo J.M., and Smith A.F.M. Bayesian theory (1994), Wiley, New York
18. Gelman A., Carlin J.B., Stern H.S., and Rubin D.B. Bayesian data analysis (1995), Chapman & Hall, London
19. Bois F.Y., and Maszle D. MCSim: a simulation program. J Stat Software 2 9 (1997). http://toxi.ineris.fr [software available online at http://toxi.ineris.fr]
20. Kohn M.C., and Melnick R.L. Physiological modeling of butadiene disposition in mice and rats. Chem-Biol Interact 135-136 (2001) 285-301
21. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., and Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol Ind Health 13 4 (1997) 407-484
22. Bischoff K.B., and Brown R.G. Drug distribution in mammals. Chem Eng Prog 66 (1966) 33-45
23. Gerlowski L.E., and Jain R.K. Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci 72 (1983) 1103-1127
24. Kashuba A.D., Ballow C.H., and Forrest A. Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime. Antimicrob Agents Chemother 40 8 (1996) 1860-1865
25. Bois F.Y., Tozer T.N., Hauck W.W., Chen M.L., Patnaik R., and Williams R.L. Bioequivalence: performance of several measures of extent of absorption. Pharm Res 11 5 (1994) 715-722
26. Ludemann L., Hamm B., and Zimmer C. Pharmacokinetic analysis of glioma compartments with dynamic Gd-DTPA-enhanced magnetic resonance imaging. Magn Reson Imaging 18 10 (2000) 1201-1214
27. Lafrance P., Lemaire V., Varin F., Donati F., Belair J., and Nekka F. Spatial effects in modeling pharmacokinetics of rapid action drugs. Bull Math Biol 64 3 (2002) 483-500
28. Oliver R.E., Jones A.F., and Rowland M. A whole-body physiologically based pharmacokinetic model incorporating dispersion concepts: short and long time characteristics. J Pharmacokinet Pharmacodyn 28 1 (2001) 27-55
29. Watanabe K., and Bois F.Y. Interspecies extrapolation of physiological pharmacokinetic parameter distributions. Risk Anal 16 (1996) 741-754
30. Bernillon P., and Bois F.Y. Statistical issues in toxicokinetic modeling: a Bayesian perspective. Environ Health Perspect 108 (2000) 883-893